Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lirilumab - Bristol-Myers Squibb/Innate Pharma

Drug Profile

Lirilumab - Bristol-Myers Squibb/Innate Pharma

Alternative Names: Anti-KIR (1-7F9); Anti-KIR monoclonal antibody - Innate Pharma; BMS-986015; IPH-21; IPH-2101; IPH-2102; NN 1975; ONO-4483

Latest Information Update: 28 Jul 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Innate Pharma; National Cancer Institute (USA); Ono Pharmaceutical; PrECOG; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; KIR receptor antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Head and neck cancer; Myelodysplastic syndromes
  • Phase I/II Solid tumours
  • Phase I Bladder cancer
  • No development reported Haematological malignancies; Lymphoma; Multiple myeloma
  • Discontinued Acute myeloid leukaemia; Hepatitis C

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy) in USA (IV, Infusion)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Jul 2019 No recent reports of development identified for preclinical development in Lymphoma in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top